Vir Biotechnology Inc
NASDAQ:VIR 2:31:02 PM EDT
| Market Cap (Intraday) | 1.06B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $7.55 |
| 50-Day MA | $7.98 |
| 200-Day MA | $9.37 |
Vir Biotechnology Inc Stock, NASDAQ:VIR
1800 Owens Street, Suite 900, San Francisco, California 94158
United States of America
Phone: +1.415.906.4324
Number of Employees: 587
Description
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.